ORIGINAL ARTICLE |
|
Year : 2021 | Volume
: 34
| Issue : 1 | Page : 285-290 |
|
Safety and efficacy of low-dose alteplase in the treatment of acute ischemic stroke in Egyptian patients
Wafik M El-Sheikh1, Gelan M Salim1, Khaled H Afifi1, Basma G El-Shanawany2
1 Department of Neuropsychiatry, Faculty of Medicine, Menoufia University, Menoufia, Egypt 2 Department of Neuropsychiatry, El-Mataria Teaching Hospital, Cairo, Egypt
Correspondence Address:
Basma G El-Shanawany Sers El-Lian, Menoufia, 12345 Egypt
Source of Support: None, Conflict of Interest: None | Check |
DOI: 10.4103/mmj.mmj_269_19
|
|
Objective
To evaluate the safety and efficacy of low-dose alteplase (0.6 mg/kg) in the treatment of Egyptian patients with acute ischemic stroke (AIS).
Background
High cost and concerns associated with post-thrombolysis intracerebral hemorrhage are major obstacles that limit utilization of the standard-dose alteplase (0.9 mg/kg) in AIS in Egypt.
Patients and methods
This is a nonrandomized clinical trial conducted on 40 Egyptian patients with AIS who were eligible for intravenous alteplase. Patients were thrombolysed at a dose of 0.6 mg/kg. Primary outcomes were safety expressed in the proportion of patients who developed symptomatic intracranial hemorrhage according to European Cooperative Acute Stroke Study III definition and 3-month mortality and efficacy expressed in the proportion of patients with modified Rankin Scale of 0–1 (favorable outcome) at 3 months.
Results
The proportion of favorable outcome (efficacy analysis) was 37.5% (n = 15). No cases developed symptomatic intracranial hemorrhage in the studied sample with an overall mortality rate of 7.5% (n = 3) with one case recorded in hospital mortality (safety analysis).
Conclusion
Intravenous alteplase at 0.6 mg/kg within 4.5 h of stroke onset could be safe and effective in routine clinical practice as a substitute of the standard dose (0.9 mg/kg) especially in developing countries like Egypt.
|
|
|
|
[FULL TEXT] [PDF]* |
|
|
|